Genentech, part of the Roche Group (SIX:RO (SIX:ROG) (OTCQX:RHHBY), revealed on Thursday that the US Food and Drug Administration (FDA) has approved a Tecentriq (atezolizumab) combination therapy for people with advanced melanoma.
Tecentriq plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) was approved for the treatment of BRAF V600 mutation-positive advanced melanoma patients.
The approval was based on results from the Phase III IMspire150 study, which showed that the addition of Tecentriq to Cotellic and Zelboraf helped people live longer without their disease worsening or death (progression-free survival), compared to placebo plus Cotellic and Zelboraf.
The supplemental Biologics License Application (sBLA) for Tecentriq was granted under Priority Review.
More Than 13% of Northwell Health Care Providers Test Positive for Antibodies
CTI BioPharma reports six months ended 30 June 2020 financial results
PreveCeutical to begin clinical trials of cannabinoid Sol-Gel under the COVID-19 programme
Celularity awarded USD750,000 CIRM grant to advance COVID-19 treatment in California
Johnson & Johnson to supply 100m doses of investigational COVID-19 vaccine to the US Government
IMV Receives Canadian Government Funding for COVID-19 Vaccine Phase 1 Clinical Study